Rahul Batra, Managing Director

Varun Batra, Joint Managing Director

India enjoys a prominent position on the global stage as a manufacturing hub for pharmaceuticals, particularly generic medicines and low-cost vaccines along with widespread manufacturing of otc medicines, bulk drugs, contract research and manufacturing, biosimilars and biologics. Supplying over 60,000 different brands for 60 therapeutic categories, India contributed to 20 percent of the total global supply for generics. Moreover, the country is renowned for housing the largest number of USFDA approved pharmaceutical plants outside the US, and following WHO and GMP certified practices, ensuring top-notch manufacturing quality.

The pharma sector continues to promise a tremendous scope for growth due to increasing healthcare demand, low manufacturing costs, skilled workforce availability, focus on innovation and quality research, investments in modern manufacturing facilities, and extensive R&D efforts in generics. Seizing these opportunities is the Haryana based Beta Drugs, a global pharma company recognized as one of the fastest growing oncology focused manufacturing firms taking bold risks and moving aggressively to launch innovative new products for the treatment of cancer. With extensive R&D capabilities, the company stands out for providing high quality yet cost-effective cancer medicines.

Cancer Focused Formulations

In the competitive landscape of pharmaceuticals manufacturing with a continuously evolving market and consumer expectations based on demands for cost-effective solutions, new formulations, high quality of the products, and easy accessibility, Beta Drugs has gained a significant competitive advantage as an integrated company. Because Beta Drugs possesses the capability to manufacture 70 percent of the necessary active pharmaceutical ingredients in house, it is able to guarantee optimal quality at much more reasonable prices.

Primarily focused on developing oncology drugs that are life-saving medicines, Beta Drugs is leveraging its extensive fifteen years of experience and expertise to manufacture these drugs, marketing in the Indian & International markets for over 40 countries, and contract manufacturing these drugs for over 50 companies spread across India.

“At Beta Drugs, our vision is to achieve a sustainable leadership in complex chemical synthesis for anti-cancer bulk drugs and finished dosages. Our mission is to touch the lives of millions of cancer patients by expanding access to quality and affordable drugs through cutting edge technology and advanced R&D. We understand patients, and how fighting a disease takes a toll on them. So, we constantly innovate to create better value and persistently focus on originality and try to find better ways to excel by creating products for current and future unmet needs”, shares Rahul Batra, Managing Director.

As a brand passionate about changing the course of cancer treatments by innovating effective medicines, the company has made great strides, and is today renowned for launching the first generic brand in the oncology market. Furthermore, the company has a brilliant pipeline of anti-cancer products which meet international quality standards, manufactured in facilities that are approved by major regulatory agencies. Beyond drug manufacturing, the company is also dedicated to supporting needy patients by offering essential medicines through its drug support program, to ensure their treatment does not stop mid way.

Assuring Quality & Sustainability

Dealing with critical life-saving drugs, Beta Drugs pays strong emphasis on quality assurance and control practices. For this, the firm has a dedicated team that oversees product quality across multiple phases of production from API production to final product manufacturing. This allows the firm to assure that the products manufactured and packaged are able to achieve maximum efficacy, aligned with the relevant dynamically changing international standards of quality.

“The quality control department is well equipped with modern instruments and systems for carrying out analysis of the raw materials, packing materials, in process or intermediate samples, finished drug substances, and microbiological analysis. Each raw material and packing material manufactured and supplied is analyzed as per laid down specifications. Specifications, standard test methods (method of analysis) and acceptance criteria are well documented and revised by the quality control department from time to time”, further shares Rahul Batra, Managing Director.

In addition to quality assurance through thorough and rigorous checks, the company also maintains strict control over resource consumption to drive its sustainability goals. The production processes are designed to reduce waste generation and energy consumption. Through these critical sustainability methods, the firm ensures seamless operations, which translates into the production of high-quality yet cost-effective medicines. At the same time, the firm helps in preserving the environment and supporting the community “Our all 4 manufacturing facilities are technically and professionally competent to handle all the associated and inherent hazards and risks while manufacturing an oncological range of APIs and formulations. As a mandatory safeguard and to ensure maximum protection to staff handling oncology products, utmost care is taken to avoid cross-contamination and possible exposure to lead hazards. Our holistic approach not only benefits our clients but also aligns with our commitment to sustainable and responsible business practices”, adds on Varun Batra, Joint Managing Director.

But, apart from these practices, what sets Beta Drugs apart from the competition is its dedicated team of seasoned professionals across varied business departments who ensure that the firm always stands true to its commitment to consistent quality. For assuring this, the teams follow a continuous improvement approach across all aspects of business, which helps in developing new formulations and enhancing drug safety and effectiveness. Moreover, this helps the firm in establishing credibility and trust among stakeholders, and fostering strong and mutually beneficial relationships.

The combined experience of these varied teams across critical areas of the pharmaceutical industry, provides the firm with an essential distinction in meeting the highest standards of production, innovation, and customer service. Each team, while performing distinct jobs, complements the other in managing its roles and responsibilities, collectively fueling the growth of the company.

Future Roadmap

“Our journey began in the early 80’s with the ardent efforts of the late Vijay Batra. He has foreseen the scope in niche segments like oncology. Today we have 125 SKUs in our Oncology product portfolio. We are one of the leading oncology companies in India having a presence in 80 percent of corporate and governmental institutes. We aim to remain a leader in the pharmaceutical industry, delivering innovative, high-quality, and cost-effective medicines to patients worldwide. Our commitment to research, sustainability, and patient-centric solutions will continue to drive our growth and success in the years to come”, lastly adds Rahul Batra, Managing Director.

As the company envisions its future roadmap, it is undertaking a multifaceted approach to growth with multiple strategies to allow for overall expansion. With continuous innovation at the heart of its ethos, the company will focus on enhancing its product portfolio further by introducing targeted therapies like PARP inhibitors, nibs and new drug delivery formulations, enhancing its manufacturing capabilities, and expanding its global presence. Currently present in over 46 countries worldwide, with recent EAEU approval, adding to its INVIMA and ANVISA approvals, the company can now access larger markets like Russia, Armenia, Belarus, and Kazakhstan. Beta Drugs is also targeting European markets for its next phase of expansion, and is gearing up to fortify its presence in other semi-regulated countries as well.

Beyond this, the firm is also focused on expanding its solutions in the skin care market and leverage its huge infrastructure to make strides in this segment. With this robust plan of action, the firm is on the way to becoming a globally preferred partner of choice for these medicines.